A phase I trial of recombinant gamma interferon in patients with cancer by Maluish, Annette E. et al.






A phase I trial of recombinant gamma interferon 
in patients with cancer* 
Kenneth A. Foon 1, Stephen A. Sherwin 2, Paul G. Abrams l, Henry C. Stevenson 1, Pamela Holmes l, Annette E. Maluish 3, 
Robert K. Oldham 1.*, and Ronald B. Herberman 1 
J Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, 
NIH, Frederick Cancer Research Facility, Frederick, MD 21701, USA, 
2 Genentech, Inc., South San Francisco, CA 94080, USA 
3 Program Resources, Inc., NCI-Frederick Cancer Research Facility, Frederick, M D 21701, USA 
Summary. A total of 11 patients were treated on an escalat- 
ing, single dose trial of recombinant gamma interferon 
(rIFN-7), 6 patients by the i.m. and 5 patients by the i.v. 
route of administration. Dose ranges within each individu- 
al were from 0.05 mg/m 2 of IFN (1 mg~> 10 x 106 units of 
IFN) escalating to 10 mg/m 2. All dosages were delivered 
twice weekly and the i.v. dose was infused over 5 min. The 
most common toxicities encountered included fever, chils, 
fatigue, anorexia, and granulocytopenia. The influenza- 
like symptoms were very similar to those encountered with 
IFN-a  but were generally less severe. The granulocytope- 
nia was dose-related and transient with recovery generally 
seen within 48-72 h following administration of rIFN-7. 
Absolute granulocyte counts only rarely dropped below 
1000 mm 3. Hepatotoxicity was not observed. IFN levels 
were determined by both a bioassay and an enzyme-linked 
immunosorbent assay. By the i.v. route, the peak level of 
IFN activity could usually be seen at completion of the in- 
fusion with a serum half-life of 30 rain. By the i.m. route, 
the peak level of serum activity was generally detected be- 
tween 4-8  h with a serum half-life of 4.5 h after the initial 
elimination phase. Peak IFN levels appeared to correlate 
with maximum toxicity. One patient with melanoma had a 
25% reduction in a cutaneous lesion, but there were no 
other minimal, partial, or complete responses. 
Introduction 
Interferons (IFNs) clearly have a wide variety of antipro- 
liferative and immunomodulatory effects, which have led 
to extensive clinical trials of various IFN preparations in 
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the treatment of patients with advanced cancer. Most of 
the trials have been phase I and phase II trials with IFN-c~. 
Trials with IFN-a have demonstrated substantial antitu- 
mor activity in favorable histology non-H0dgkin's lym- 
phoma [9, 12, 17, 19, 26], cutaneous T-cell lymphoma [31, 
hairy cell leukemia [23], kaposi's sarcoma [11, 16], and 
chronic myelogenous leukemia [30]. Activity has been re- 
ported for myeloma [12, 20], breast cancer [15, 27], renal 
cell carcinoma [22], and melanoma [4], but considerably 
less activity than that described for the hematopoietic 
malignancies described above. Recently, recombinant 
1FN-[3 and natural and recombinant IFN-7 (rlFN-7) have 
been brought into clinical trials. 
IFN-7 has distinct antiproliferative and immunomodu- 
latory properties from IFN-c~ and IFN-[3, which might re- 
sult in a different array of clinical effects. In early studies, 
IFN- 7 was shown to have more potent antiproliferative ef- 
fects than the other IFN preparations [25]. However, many 
of these studies were performed with only partially puri- 
fied IFN-y preparations that may have contained other bi- 
ologically active molecules. Recent evidence suggests, 
however, that IFN-7 has antiproliferative activity and in 
certain instances, the spectrum of activity differs from 
IFN-c~ and IFN-[3 depending on the tumor cell type being 
tested. IFN-7 has been shown to synergize with IFN-c~ and 
IFN-[3 in in vitro antiproliferative assays using various hu- 
man tumor cell lines [5, 8]. IFN-7 interacts with a different 
cell surface receptor than IFN-c~ and IFN-13 which ex- 
plains the rationale for possible synergy between IFN-7 
and either IFN-a or IFN-[3 [2]. IFN-7 has also been shown 
to have potent macrophage activating effects, including in- 
duction of tumoricidal and microbicidal activity [15]. IFN- 
7 is thought to be the s a m e  molecule as macrophage acti- 
vating factor by some investigators [29]. Augmentation of 
antibody-dependent cellular cytotoxicity [14], stimulation 
of peroxide generation [21], and enhancement of expres- 
sion of Fc receptors, HLA-DR antigens, and class I histo- 
compatibility antigens on the cell surface have been de- 
scribed [1]. IFN-cx and IFN-~ are not as effective as IFN-7 
in enhancing class I and class II histocompatibility anti- 
gens [6, 7, 18]. These activities might be expected to make 
IFN-y a potent biological response modifier in cancer pa- 
tients and thus warrant the clinical evaluation of IFN-7 in 
the treatment of patients with cancer. 
The gene for IFN-7 has been successfully cloned and 
expressed in E s c h e r i c h i a  coli  [10]. The nucleotide and ami- 
no acid sequences of rIFN=y were determined to be ident- 
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ical to native IFN-7, except for the presence of a methio- 
nine residue at the N-terminal [24]. In this paper, we report 
the results of a phase I trial with a r IFN-y in patients with 
disseminated cancer. Patients received escalating single 
doses on a twice weekly schedule by i.m. or i.v. routes of 
administration and were monitored for evidence of clini- 
cal effects, levels of circulating IFN, and immunomodula- 
tory effects. We report here the clinical and pharmacokin- 
etic results. 
Materials and methods 
rlFN-y preparation, rlFN-5, was prepared using recombi- 
nant DNA technology (Genentech, Inc., South San Fran- 
cisco, Calif.). The final product was >98% pure as deter- 
mined by sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis. Sterility, purity, pyrogenicity, and general 
safety met the standards of the Office of Biologics. Tests 
for endotoxin in the limulus assay routinely revealed 
< 0.5 ng/mg protein. Acute and subacute toxicology stud- 
ies were carried out in two species (the rat and the squirrel 
monkey), and no significant toxicity was observed. The 
specific activity of r lFN- 7 was t> 1 x 10 7 units/mg protein 
based on an antiviral bioassay with encephalomyocarditis 
virus and human A549 cells (standardized with NIH IFN- 
5' standard Gg 23-901-530). 
Patient selection. A total of 11 patients with disseminated 
malignancy refractory to standard therapy were entered 
onto this trial (Table 1). All patients were required to have 
an ambulatory performance (Karnofsky) score of 60%, no 
intervening anticancer therapy for a minimum of 4 weeks, 
and adequate hematologic (white blood cell count 
>4000/mm 3, platelet count < 100.000 mm3), hepatic (bi- 
lirubin ~< 1.5 mg/dl), and renal (creatinine < 2 m g / d l )  
function. Informed consent was obtained from all patients 
prior to the initiation of therapy. 
Study design. Patients received escalating single doses of 
r lFN-y by either i.m. or i.v. administration on a twice 
weekly schedule for seven or eight doses, respectively. One 
injection was given at each of the following dose levels: 
0.05, 0.1., 0.25, 0.5, 1, 2.5, 5, and 10 mg /m 2 (10 mg /m 2 was 
given i.v. only). All i.v. doses of rIFN-7 were administered 
by infusion over a period of 5 min. Dosage escalation con- 
tinued in the absence of unacceptable systemic toxicity or 
tumor progression. The 10 mg /m 2 dose was not given i.m. 
Table 1. Patients entered on rlFN-y trial 
Intramuscular Intravenous 
Number 6 5 
Age (median) 45 - 64 18 - 71 
Sex (M/F) 5/1 2/3 
Diagnosis: 
Melanoma 2 2 
Adenocarcinoma lung 1 
Multiple myeloma 2 
Renal cell carcinoma 2 
Giant cell sarcoma 1 
Hairy cell leukemia 1 
because an excessive injection volume of the available for- 
mulation would have been required. 
The half-life for the i.v. route was calculated using non- 
linear least square fit of a one compartment model, and 
for the i.m. route using a linear least square fit of the termi- 
nal portion of individual patient log concentration time 
curves. 
Patient monitoring. Prior to the initiation of therapy, all 
patients underwent a history and physical examination, 
complete blood counts, serum chemistry profiles, chest x- 
ray, electrocardiogram, and radiologic studies as appropri- 
ate for documentation of the extent of their disease. Fol- 
lowing each injection of rIFN-5', patients were carefully 
monitored for toxicity by repeated physical examinations, 
complete blood counts, and serum chemistry profiles. 
Reassessment of the extent of the disease to determine an- 
titumor activity was performed as clinically indicated, dur- 
ing the course of the study or at its conclusion. All patients 
were monitored for levels of serum IFN, using an antiviral 
biological assay with encephalomyocarditis virus and hu- 
man A549 lung carcinoma cells and by an enzyme-linked 
immunosorbent assay (ELISA) using a polyclonal antiser- 
um to rlFN-5' with limits of detectability to 0.01 ng/ml. 
Results 
Clinical summary 
Of the patients who entered the study, 6 received i.m. and 
5 received i.v. administrations. One patient with hairy cell 
leukemia was removed from the study after only one i.m. 
dose of r lFN-7 as it was determined that his granulocyte 
count was too low to be followed adequately for potential 
IFN-related toxicity. Another patient treated with i.m. 
rIFN- 7 was removed after one dose due to abnormal liver 
function tests not related to the IFN therapy. Another pa- 
tient with multiple myeloma was removed from the i.m. 
dose after three doses due to hypercalcemia. One patient 
with melanoma did not complete the i.v. therapy (three 
doses) due to abdominal pain that was subsequently deter- 
mined to be secondary to an ovarian cyst. 
The most notable toxicity was fatigue, which was clearly 
dose-related, with the degree of fatigue increasing with in- 
creasing doses of rlFN-5', and it was more prolonged by 
the i.m. route of administration. The degree of fatigue ap- 
peared to be dose-limiting at 5 mg /m 2 by both routes of 
administrations with patients essentially bedridden for 
12 h following this dose. Body temperature was i> 39°C in 
only one patient at the 5 m g / m  2 i.m. dose. Onset of fevers 
were demonstrated from 2 - 4  h (peak at 6 -8  h) following 
the i.m. dose and usually occurred within 1-2 h (peak at 
4 - 6  h) following the i.v. dose. Hypotension with a systolic 
blood pressure < 90 mm Hg was seen in only one patient 
treated with i.v. rlFN-5' at 0.25 mg /m 2 and another at 
5 mg /m 2. A depression of granulocytes was common, but 
only two patients experienced granulocytopenia with be- 
tween 500 and 1000 granulocytes/mm 3 (1 at 0.25/m 2 i.v. 
and another at 5 m g / m  2 i.m.). There was no depression of 
any other blood components including lymphocytes, 
platelets, and eryhtrocytes. There were no changes in ser- 
um chemistry profiles (except for those mentioned above) 
or physical findings. 





Temperature (° F) Chills Fatigue Nausea Vomiting 
99-100 101-102.9 ~> 103 
Hypotension 
(systolic < 
90 mm Hg) 
Granulocytopenia 
(mm 3) 
500- 1000 < 500 
0.05 6 3 2 0 3 1 0 0 0 
0.1 4 4 0 0 2 3 0 0 0 
0.25 4 3 1 0 0 3 0 0 0 
0.5 3 2 1 0 2 3 0 1 0 
1.0 3 1 2 0 2 3 0 1 0 
2.5 3 0 3 0 2 3 0 1 0 
5.0 3 0 2 1 3 3 1 1 0 
i . g .  
0.05 5 3 2 0 1 1 0 0 0 0 
0.1 5 2 3 0 3 2 0 0 0 0 
0.25 5 1 3 0 4 2 0 0 1 1 
0.5 4 1 3 0 4 2 1 0 0 0 
1.0 4 2 2 0 3 3 1 0 0 0 
2.5 4 2 2 0 4 3 1 1 0 0 
5.0 4 1 3 0 3 3 2 3 1 0 
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Fig. 1. Pharmacokinetics of serum rIFN-y af ter  (A) i.v. or (B) i.m. administration of rIFN-y measured by an ELISA with standard 
deviations 
Antitumor activity 
N o  par t ia l  or  c o m p l e t e  responses  were  seen in any  o f  the 
pat ients  t rea ted  with  r I F N - y  in this study. O n e  pa t ien t  wi th  
m e l a n o m a  t rea ted  by the i.m. rou te  had  a m i n o r  regress ion  
o f  her  only  measu rab l e  disease which  was a cu taneous  le- 
s ion and  was t rea ted  for  1 add i t iona l  m o n t h  with  0.25 m g /  
m 2 wi thout  fur ther  change.  O n e  pa t ien t  wi th  mul t ip l e  mye-  
l o m a  d e m o n s t r a t e d  l ikely progress ive  disease g rowth  fol- 
lowing  the th i rd  dose  o f  r I F N - y ,  as ev idenced  by increa-  
sing hype rca l cemia ,  which  requ i red  d i s con t inua t ion  o f  
r I F N - y  therapy.  O n e  pa t ien t  wi th  renal  cell  c a r c i n o m a  
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completed  the study but  demonst ra ted  minimal  disease 
progression,  and all of  the other patients remained stable. 
Serum IFN levels 
Serum I F N  activity was measured by both a biological  an- 
t iviral  assay and by an ELISA. Serum r I F N - y  levels were 
rout inely found by  both  the i.v. and i.m. routes of  adminis-  
t rat ion (Fig. 1). Detectable levels of  I F N  by the ELISA in 
n g / m l  were consistently found by both the i.m. and  i.v. 
routes at the lowest dose of  I F N  (0.05 m g / m  2) adminis-  
tered. The pat terns  of  the curves of  the bioassay general ly  
para l le led the results of  the ELISA al though the bioassay 
did not  detect activity by the i.m. route at doses below 
1 m g / m  2, whereas, detectable levels could be measured in 
the bioassay as well as E L I S A  at all doses by the i.v. route. 
These data  clearly demonstra te  a dose-dependent  peak  le- 
vel of  serum r I F N - y  by  both the i.m. and  i.v. routes. The 
serum half-life was approx imate ly  30 rain by the iv.v. route 
and 4.5 h for the e l iminat ion phase fol lowing the i.m. in- 
ject ion.  Ant ibodies  ro r IFN-7  (by both a neutral izing an- 
t ibody  detect ion assay and an immunoassay  for ant ibody)  
were tested for in 8 o f  11 patients on this trial,  and  none 
were detected. 
Discussion 
In this paper ,  we repor t  the results of  a r IFN-7  study for 
patients with disseminated cancer. Our results indicate  that  
r IFN-7  can be given by both the i.m. and  i.v. routes with 
serum levels measured in an ELISA at all doses 
(0.05-10 m g / m  2) and in a biological  assay at all doses by 
the i.v. route and at i> 1 m g / m  2 by the i.m. route. Previous 
studies with nonrecombinan t  I F N - y  at comparab le  doses 
to those used in the current  study repor ted  no detectable 
serum levels fol lowing the i.m. route of  adminis t ra t ion  [13, 
28]. In both of  these other studies measurements  were car- 
ried out by a bioassay rather than an ELISA,  with the lat- 
ter having a sensitivity of  0.01 ng /ml .  Al though we did de- 
tect serum I F N  by the i.m. route using our bioassay,  it was 
only at i.m. doses greater than those repor ted in these other 
studies. The serum half-life fol lowing the i.v. dose of  r I F N -  
~, of  30 rain was very similar to previous reports  for i.v. bo- 
lus natural  I F N - 7  [13, 28]. Toxicities were very similar  to 
those repor ted for natural  I F N - 7  as well as IFN-t~. The 
precise maximum tolerated dose for single dose adminis-  
t rat ion could not  be accurately assessed due to the poten-  
tial cumulative toxici ty of  r I F N - 7  by the single dose escal- 
ation design of  this study. Toxicities included fatigue, 
fever, chills, anorexia,  occasional  nausea and vomiting,  
headaches,  mild hypotension,  and granulocytopenia .  
Pharmacokinet ic  da ta  revealed a relatively rap id  clear- 
ance for the i.v. adminis tered  r I F N - y  and a more pro-  
longed serum level by the i.m. route, with activities still de- 
monstrable  at all dose levels 24 h after the injection. As 
might  be expected,  the toxicit ies of  the i.m. route were later 
in onset and more prolonged.  
Immunolog ic  studies will be repor ted separately.  An 
op t imum biological  response modifying dose was not  de- 
termined in this study. Future  trials with r IFN-7  should fo- 
cus on determining an op t imum biological  response modi-  
fying dose. Possibly, the op t imum biological  response 
modify ing  dose is at a very low dose and we may have 
been unable  to identify it because of  our rap id  dose escala- 
tion. 
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